Skip to content
Screener

Ligand Pharmaceuticals LGND Gross margin

Discontinued — last reported Q3 '19

Gross margin at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
98.2%-0.7pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
72.2%-10.9pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
93.4%+3.7pp
Opko Health logo
Opko HealthOPK
40.8%+8.1pp
Regenxbio logo
RegenxbioRGNX
59.7%+1.0pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
95.5%+23.5pp

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.06B+119%
Enterprise value$6.19B+129%
P/E30.8×—
P/S20.9×+6.1×

Profitability

See full
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

gross profit/total revenue=91.9%

Based on trailing twelve months.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed November 6, 2020. Open the filing →

Filed
Nov 6, 2020, 4:11 PM EST
Fiscal quarter
Q3 FY2020
Calendar quarter
Q3 2020
Accession
0000886163-20-000122

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.